Compare Global X CleanTech (CTEC) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X CleanTech vs Novo Nordisk A/S — how do they compare? Global X CleanTech trades at $58.44, while Novo Nordisk A/S trades at $45.76 (market cap $207.85B). The key difference: Novo Nordisk A/S pays a 3.81% dividend while Global X CleanTech pays none, and Global X CleanTech is trading nearer its 52-week high, Novo Nordisk A/S nearer its low. Which is the better fit depends on your goals.
| CTEC | NVO | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $78.11 | $63.98 |
52-Week Low | $41.08 | $35.29 |
Market Cap | — | $207.85B |
Enterprise Value | — | $222.55B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTEC trades at $58.40, up 2.1% today, with a neutral technical signal overall. Moving averages suggest a bullish trend, while oscillators are neutral. The stock faces resistance near $60 and support at $53. A dividend of $0.07 is scheduled for July 2026. Key financial ratios are currently unavailable.
The outlook hinges on upcoming financial disclosures to assess fundamentals. Near-term price action may test resistance at $60. Risks include lack of recent financial data and market volatility. Investor sentiment appears balanced pending further company updates.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X CleanTech
CTEC invests in companies at the forefront of the clean technology industry. It focuses on disruptive innovations in renewable energy production, energy storage, smart grids, and energy efficiency, with top holdings like Enphase and First Solar.
Read more on CTEC →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
